# Safety and Diagnostic Performance of uPAR PET Imaging in Localised, Untreated Prostate Cancer

Source: https://onco.cc/trials/nct06474806/  
OnCo record `nct06474806` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of 64Cu-DOTA-AE105 in prostate cancer, run by Curasight, now recruiting.

## Summary

Safety and Diagnostic Performance of uPAR PET Imaging in Localised, Untreated Prostate Cancer is a phase 2 interventional study registered as NCT06474806 by Curasight, with 168 participants planned, started 2024-06-01 and due to reach its primary completion in 2027-01-30. Interventions recorded: 64Cu-DOTA-AE105.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06474806
- Phase: 2
- Setting: An Open-label, Two-part, Phase 2 Clinical Trial to Investigate the Safety and Diagnostic Performance of uPAR PET Imaging for Non-invasive Classification of ISUP Grades Among Patients With Localised, Untreated Prostate Cancer.
- Sponsor: Curasight
- Enrolled: 168

## Sources

- ClinicalTrials.gov NCT06474806: https://clinicaltrials.gov/study/NCT06474806

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)

---
JSON: https://onco.cc/api/v1/entities/nct06474806.json